Abstract: In recent years, myelin oligodendrocyte glycoprotein antibody (MOG-IgG)-associated optic neuritis (MOG-ON) has gradually become a research focus in neuro-ophthalmology. The bilateral incidence of MOG-ON is relatively high, accompanied by obvious optic disc edema, and the enhancement of the optic nerve sheath and adjacent tissues can be seen on MRI. The likelihood of recurrence is high, but the prognosis of MOG-ON is usually better than that of aquaporin-4 antibody (AQP4-IgG) associated optic neuritis. At present, the optimal treatment plan for MOG-ON is still in the exploratory stage. Hormone shock is effective in the acute phase, and long-term immunotherapy was usually required for the relapsing patients. Targeted therapy such as rituximab and tocilizumab has gradually become a research hotspot to reduce the recurrence rate.

Key words: Myelin oligodendrocyte glycoprotein, Demyelination, Optic neuritis